Ardelyx shareholders invited to join class action lawsuit
Shareholders of Ardelyx, Inc. are being notified of a pending securities fraud lawsuit alleging violations of federal exchange acts.

Legal firm Schall, Brown & Schwartz LLP has announced it is representing investors in a class action lawsuit against Ardelyx, Inc. The litigation alleges that the biopharmaceutical company violated sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
The lawsuit centers on claims that the company made misleading statements to shareholders regarding its business practices. Investors who acquired shares within the relevant class period are eligible to participate in the litigation to seek potential recovery of financial losses.
This legal action highlights the ongoing regulatory and investor scrutiny facing the company. Ardelyx, which specializes in renal and cardiorenal disease treatments, must now navigate these legal proceedings while continuing its commercial operations. The court has set a deadline for investors to apply as lead plaintiffs.